A Phase 4 interventional study of cyclosporin (Neoral) and tacrolimus (Prograf) in Hepatitis C and Liver Transplantation, sponsored by Novartis Pharmaceuticals. Completed at 45 sites in 13 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2015-05-22.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Hepatitis C by Novartis — none open to participants now, none under way, none of them phase 3. Hepatitis C · Novartis.
Among the 10 studies in Hepatitis C by Novartis, this one is the only one that started in 2009, is one of 2 in phase 4, and was the 5th registered.
1,744 studies on the registry are indexed under Hepatitis C; 98 are open to participants now.
Browse Hepatitis C studies →None of the 10 studies in Hepatitis C by Novartis is open now. The open studies under Hepatitis C, anywhere →
Of the 56 Hepatitis C studies recruiting now, 43 (77%) set no upper age limit and 6 (11%) stop at 75 or younger; 10 take children under 18; 26 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 3 · Phase 3 3 · Phase 4 2
First in 2002; this study’s year is marked. 1 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 92 is above the median of 73 across 1,224 interventional studies indexed under Hepatitis C.
Median enrollment 76 across the 8 interventional studies, 22 across the 1 observational. Of the 9 that completed or were terminated, 4 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 10 studies in Hepatitis C by Novartis, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will assess the rates of Sustained Virological Response following anti-viral therapy with Peg-Interferon plus Ribavirin in patients that have been liver transplanted with recurrent Hepatitis C and treated with Neoral or tacrolimus.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Neoral capsules bid, Doses were to be adjusted as necessary to achieve and maintain recommended C0 (monitoring of trough levels) or C2 concentration 2 hours post dosing) target ranges
Drug: cyclosporin (Neoral)
Tacrolimus capsules bid, doses were adjusted as necessary to achieve and maintain recommended C0 target ranges.
Drug: tacrolimus (Prograf)
Neoral capsules bid, Doses were to be adjusted as necessary to achieve and maintain recommended C0 (monitoring of trough levels) or C2 concentration 2 hours post dosing) target ranges
Tacrolimus capsules bid, doses were adjusted as necessary to achieve and maintain recommended C0 target ranges.
Number of Participants Sustained Virological Response (SVR) Following Treatment of Hepatitis C Virus (HCV) Infection With Peg-IFN and Ribavirin in Liver Transplanted Recipients on Maintenance Therapy With Neoral or Tacrolimus
The achievement of SVR, defined as HCV RNA below limit of detection at the end of AV treatment, 24 weeks after end of AV treatment (W24 post). A dichotomous variable (SVR achieved: Yes/No) was computed. A patient was classified as non-responder (SVR not achieved) if HCV RNA was detectable at the completion of antiviral treatment, at W24post, or at any time between W24 and completion of antiviral treatment. The HCV RNA detection limit was \<15 IU/ml (\<1.18 log IU/ml)
Time frame: Week 24
Number of Events of the Composite Endpoint of Biopsy Proven Acute Rejections (BPAR), Death or Graft Loss and of the Individual Components
Efficacy failure (biopsy proven acute rejection (BPAR), graft loss, or death
Time frame: Week 80
Number of Participants With Fibrosis Progression (Increase in Ishak-Knodell (IK) Score by at Least One Point From the Baseline)
Ishak-Knodell Score: 0=No fibrosis; 01=Fibrous expansion of some portal areas, with or without short fibrous septa; 02=Fibrous expansion of most portal areas, with or without short fibrous septa; 03=Fibrous expansion of most portal areas, with occasional portal to portal (P-P) bridging; 04=Fibrous expansion of portal areas, with marked bridging (portal to portal (P-P) as well as portal to central (P-C)); 05=Marked bridging (P-P and/or P-C) with occasional nodules (incomplete cirrhosis); 06=Cirrhosis, probable or definite, Participants showing an increase of Ishak Knodell fibrosis score by at least one level (increase of ≥1)
Time frame: Week 80
Number of Participants of Rapid Viral Response (RVR)
RVR defined as non-detectable HCV RNA 4 weeks after initiation of antiviral treatment. The HCV RNA detection limit was \<15 IU/ml (\<1.18 log IU/ml)
Time frame: Week 4
Number of Participants of Early Viral Response (EVR)
EVR defined as non-detectable HCV RNA or a ≥2 logs reduction of HCV RNA at 12 weeks after initiation of antiviral treatment. The HCV RNA detection limit was \<15 IU/ml (\<1.18 log IU/ml)
Time frame: Week 12
Number of Participants for the End of Treatment Response (ETR)
ETR defined as non-detectable HCV RNA at the completion of AV treatment. The HCV RNA detection limit was \<15 IU/ml (\<1.18 log IU/ml)
Time frame: Week 80
Number of Participants of True Non-responder Rate
Defined as failure to achieve at least a 2 log reduction of Hepatitis C virus (HCV) RNA. The HCV RNA detection limit was \<15 IU/ml (\<1.18 log IU/ml)
Time frame: Week 80
Number of Participants for Relapse Rate
Defined as reappearance of detectable Hepatitis C Virus (HCV) RNA at 24 weeks after completion of antiviral treatment when HCV RNA was undetectable at the end of treatment. The HCV RNA detection limit was \<15 IU/ml (\<1.18 log IU/ml)
Time frame: Week 24
Number of Participants With Dose Reduction or Discontinuation of Antiviral (AV) Therapy Due to Poor Tolerability at Any Time During the Study for Any Reason
Defined as number of patients with dose reduction or discontinuation of AV therapy due to poor tolerability
Time frame: Week 80
| Milestone | Neoral | Tacrolimus |
|---|---|---|
| Started | 50 | 42 |
| Efficacy population | 40 | 41 |
| Completed | 25 | 25 |
| Not completed | 25 | 17 |
| Withdrew: Adverse event | 2 | 1 |
| Withdrew: Abnormal laboratory values | 2 | 2 |
| Withdrew: Withdrawal by subject | 11 | 8 |
| Withdrew: Lost to follow-up | 4 | 4 |
| Withdrew: Administration problems | 2 | 0 |
| Withdrew: Death | 1 | 1 |
| Withdrew: Protocol violation | 3 | 1 |
The achievement of SVR, defined as HCV RNA below limit of detection at the end of AV treatment, 24 weeks after end of AV treatment (W24 post). A dichotomous variable (SVR achieved: Yes/No) was computed. A patient was classified as non-responder (SVR not achieved) if HCV RNA was detectable at the completion of antiviral treatment, at W24post, or at any time between W24 and completion of antiviral treatment. The HCV RNA detection limit was \<15 IU/ml (\<1.18 log IU/ml)
| Participants | Neoral | Tacrolimus |
|---|---|---|
| Number of Participants Sustained Virological Response (SVR) Following Treatment of Hepatitis C Virus (HCV) Infection With Peg-IFN and Ribavirin in Liver Transplanted Recipients on Maintenance Therapy With Neoral or Tacrolimus | 12 | 10 |
Efficacy failure (biopsy proven acute rejection (BPAR), graft loss, or death
| Number of events | Neoral | Tacrolimus |
|---|---|---|
| BPAR, graft loss, or death | 2 | 1 |
| BPAR | 1 | 0 |
| Graft loss or death | 1 | 1 |
| Death | 1 | 1 |
Ishak-Knodell Score: 0=No fibrosis; 01=Fibrous expansion of some portal areas, with or without short fibrous septa; 02=Fibrous expansion of most portal areas, with or without short fibrous septa; 03=Fibrous expansion of most portal areas, with occasional portal to portal (P-P) bridging; 04=Fibrous expansion of portal areas, with marked bridging (portal to portal (P-P) as well as portal to central (P-C)); 05=Marked bridging (P-P and/or P-C) with occasional nodules (incomplete cirrhosis); 06=Cirrhosis, probable or definite, Participants showing an increase of Ishak Knodell fibrosis score by at least one level (increase of ≥1)
| Participants | Neoral | Tacrolimus |
|---|---|---|
| Number of Participants With Fibrosis Progression (Increase in Ishak-Knodell (IK) Score by at Least One Point From the Baseline) | 3 | 5 |
RVR defined as non-detectable HCV RNA 4 weeks after initiation of antiviral treatment. The HCV RNA detection limit was \<15 IU/ml (\<1.18 log IU/ml)
| Participants | Neoral | Tacrolimus |
|---|---|---|
| Number of Participants of Rapid Viral Response (RVR) | 4 | 5 |
EVR defined as non-detectable HCV RNA or a ≥2 logs reduction of HCV RNA at 12 weeks after initiation of antiviral treatment. The HCV RNA detection limit was \<15 IU/ml (\<1.18 log IU/ml)
| Participants | Neoral | Tacrolimus |
|---|---|---|
| Number of Participants of Early Viral Response (EVR) | 28 | 30 |
ETR defined as non-detectable HCV RNA at the completion of AV treatment. The HCV RNA detection limit was \<15 IU/ml (\<1.18 log IU/ml)
| Participants | Neoral | Tacrolimus |
|---|---|---|
| Number of Participants for the End of Treatment Response (ETR) | 24 | 27 |
Defined as failure to achieve at least a 2 log reduction of Hepatitis C virus (HCV) RNA. The HCV RNA detection limit was \<15 IU/ml (\<1.18 log IU/ml)
| Participants | Neoral | Tacrolimus |
|---|---|---|
| Number of Participants of True Non-responder Rate | 7 | 5 |
Defined as reappearance of detectable Hepatitis C Virus (HCV) RNA at 24 weeks after completion of antiviral treatment when HCV RNA was undetectable at the end of treatment. The HCV RNA detection limit was \<15 IU/ml (\<1.18 log IU/ml)
| Participants | Neoral | Tacrolimus |
|---|---|---|
| Number of Participants for Relapse Rate | 5 | 7 |
Defined as number of patients with dose reduction or discontinuation of AV therapy due to poor tolerability
| Participants | Neoral | Tacrolimus |
|---|---|---|
| Neoral Antiviral treatment: Ribavirin | 25 | 0 |
| Neoral Antiviral treatment: Peg-IFN | 10 | 0 |
| Tacrolimus Antiviral treatment: Ribavirin | 0 | 23 |
| Tacrolimus Antiviral treatment: Peg-IFN | 0 | 11 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Tacrolimus | — | 17/42 (40.5%) | 41/42 (97.6%) |
| Neoral | — | 18/50 (36%) | 42/50 (84%) |
| Event | Tacrolimus | Neoral |
|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 5/42 | 6/50 |
| PyrexiaGeneral disorders | 3/42 | 2/50 |
| Urinary tract infectionInfections and infestations | 0/42 | 3/50 |
| Abdominal pain upperGastrointestinal disorders | 2/42 | 0/50 |
| DiarrhoeaGastrointestinal disorders | 2/42 | 0/50 |
| CholestasisHepatobiliary disorders | 2/42 | 0/50 |
| EncephalopathyNervous system disorders | 2/42 | 1/50 |
| SyncopeNervous system disorders | 2/42 | 0/50 |
| Abdominal painGastrointestinal disorders | 1/42 | 2/50 |
| AstheniaGeneral disorders | 1/42 | 2/50 |
| Event | Tacrolimus | Neoral |
|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 28/42 | 27/50 |
| NeutropeniaBlood and lymphatic system disorders | 14/42 | 6/50 |
| FatigueGeneral disorders | 13/42 | 12/50 |
| DiarrhoeaGastrointestinal disorders | 11/42 | 9/50 |
| NauseaGastrointestinal disorders | 11/42 | 6/50 |
| AstheniaGeneral disorders | 10/42 | 7/50 |
| LeukopeniaBlood and lymphatic system disorders | 9/42 | 10/50 |
| DizzinessNervous system disorders | 8/42 | 4/50 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 8/42 | 5/50 |
| HypertensionVascular disorders | 4/42 | 9/50 |
Intent-to-Treat (ITT) population: The ITT population consisted of all randomized patients.
| Age, Continuous(Years) | Neoral | Tacrolimus | Total |
|---|---|---|---|
| Mean | 54.2 ± 6.30 | 55.0 ± 6.84 | 54.6 ± 6.53 |
| Sex: Female, Male(Participants) | Neoral | Tacrolimus | Total |
|---|---|---|---|
| Female | 9 | 8 | 17 |
| Male | 41 | 34 | 75 |
The record gives a start of Sep 2009, a primary completion of May 2013 and a completion of May 2013. It does not say whether these dates are actual or estimated.
Results were first posted in May 2014, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cyclosporine